Compare BON & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | ASBP |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.0M |
| IPO Year | 2021 | N/A |
| Metric | BON | ASBP |
|---|---|---|
| Price | $1.70 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.8K | ★ 42.7M |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $21,610,848.00 | $1,941.00 |
| Revenue This Year | $223.38 | N/A |
| Revenue Next Year | $18.82 | N/A |
| P/E Ratio | $0.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $0.07 |
| 52 Week High | $73.75 | $15.80 |
| Indicator | BON | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 44.01 |
| Support Level | $1.45 | $0.10 |
| Resistance Level | $1.73 | $0.17 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.64 | 13.33 |
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.